Summary of subjects’ characteristics
| Subject | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| Gender | Female | Male | Female | Female | Female | Female | Female | Female |
| OI status | Affected | Affected | Unaffected | Affected | Affected | Affected | Unaffected | Affected |
| POAG | Yes | Yes | No | No | No | No | No | No |
| Topical Treatment | PA+CAI | PA | Nil | Nil | Nil | Nil | Nil | Nil |
| Positive findings on clinical examination | Glaucomatous cupping | Iris TID, glaucomatous cupping | Iris TID | Nil | Nil | Iris TID | Nil | Nil |
| IOP GAT (mmHg) | 26 (untreated) | 24 (treated) | 17 | 22 | 16 | 21 | 12 | 18 |
| IOPcc (mmHg) | 25 (treated) | 34 (treated) | 19 | 28 | 19 | 25 | 19 | 20 |
| CCT (µm) | 483 (treated) | 440 (treated) | 584 | 479 | 474 | 508 | 568 | N/A |
| CH (mmHg) | 8.8 (treated) | 5.8 (treated) | 12.4 | 7.5 | 7.8 | 9.2 | 12.3 | 8.4 |
An average reading from both eyes of each subject is used. Note subjects 1 and 2 were on treatment at the time of data collection. An untreated IOP GAT for subject 1 is used; all other measurements are labelled as ‘treated’. Note no CCT available for subject 8.
CAI, carbonic anhydrase inhibitor; CCT, central corneal thickness measured by Pachmate 2; CH, corneal hysteresis measured by Ocular Response Analyser; IOPcc, cornea-corrected intraocular pressure measured by Ocular Response Analyser; IOP GAT, Intraocular pressure measured by Goldmann applanation tonometry; Iris TID, iris transillumination defects; OI, osteogenesis imperfecta; PA, prostaglandin analogue; POAG, primary open-angle glaucoma.